# Matterworks

> Matterworks is a Somerville, Massachusetts biotech-AI company building foundation models for molecular biology. Its Large Spectral Models (LSMs) are trained on billions of mass spectrometry spectra and read raw molecular signals directly, turning slow, manual mass-spec workflows into automated, untargeted absolute quantitation. Its flagship cloud platform, Pyxis, acts as a predictive omics assistant that converts raw LC-MS data into identified, quantified molecules and biological insight - making mass spectrometry usable by any biologist rather than only specialist analysts.

- **Founded:** 2019
- **Headquarters:** Somerville, Massachusetts, United States
- **Founders:** Jack Geremia (CEO & Co-Founder), Mimoun Cadosch Delmar (CTO & Co-Founder)
- **Team size:** ~45 employees
- **Products:** Large Spectral Models (LSMs), Pyxis, Model-as-a-Service (MaaS)
- **Notable:** Launched Pyxis (June 2024), described as the first AI-powered, turn-key platform for identification and absolute quantitation from mass-spectrometry data., Built Large Spectral Models trained on billions of spectra - described as the first self-supervised machine intelligence for multi-omic data., LSM-MS2 reported state-of-the-art spectral identification: ~30% improvement on challenging isomeric compounds and ~42% more correct identifications in complex biological samples.

## Products & services

- **Large Spectral Models (LSMs)** — Self-supervised foundation models trained on billions of mass-spectrometry spectra that learn chemical and biological relationships directly from raw signals, enabling interpretation of complex molecular-omic data in minutes.
- **Pyxis** — Cloud-based AI platform - a 'predictive omics assistant' - that performs untargeted absolute quantitation from LC-MS data, eliminating manual per-analyte calibration, peak selection and data integration, and turning raw spectra into identified, quantified molecules and biological insight.
- **Model-as-a-Service (MaaS)** — Matterworks' commercial model that delivers its spectral models to life-science customers across drug discovery, toxicology, clinical development, and biomanufacturing/CMC.

## Achievements

- Launched Pyxis (June 2024), described as the first AI-powered, turn-key platform for identification and absolute quantitation from mass-spectrometry data.
- Built Large Spectral Models trained on billions of spectra - described as the first self-supervised machine intelligence for multi-omic data.
- LSM-MS2 reported state-of-the-art spectral identification: ~30% improvement on challenging isomeric compounds and ~42% more correct identifications in complex biological samples.
- Secured Series A financing in June 2025 led by Lewis & Clark Partners and OMX Ventures.

## Latest updates

- **2025-06** — Secured Series A funding led by Lewis & Clark Partners and OMX Ventures to grow its model-as-a-service business and expand ML and scientific operations.
- **2024-06** — Launched Pyxis, an AI-powered turn-key platform for untargeted absolute quantitation from mass-spectrometry data.
- **2025-10** — Published LSM-MS2 foundation-model research bridging spectral identification and biological interpretation.

## Links

- Website: https://matterworks.ai
- LinkedIn: https://www.linkedin.com/company/matterworksbio
- Twitter/X: https://twitter.com/matterworks_bio

---

Profile page: https://yespress.io/matterworks
Published by YesPress — https://yespress.io
Last updated: 2026-06-13